The estimated Net Worth of Julia A Haller is at least $740 mil dollars as of 3 June 2022. Julia Haller owns over 2,949 units of Bristol-Myers Squibb Co stock worth over $661,747 and over the last 8 years he sold BMY stock worth over $0. In addition, he makes $78,413 as Independent Director at Bristol-Myers Squibb Co.
Sign up
Julia Haller BMY stock SEC Form 4 insiders trading
Julia has made over 11 trades of the Bristol-Myers Squibb Co stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 2,949 units of BMY stock worth $143,292 on 3 June 2022.
The largest trade he's ever made was exercising 2,949 units of Bristol-Myers Squibb Co stock on 3 June 2022 worth over $143,292. On average, Julia trades about 333 units every 39 days since 2016. As of 3 June 2022 he still owns at least 13,619 units of Bristol-Myers Squibb Co stock.
You can see the complete history of Julia Haller stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Julia Haller biography
Dr. Julia A. Haller serves as Independent Director of the Company. She served Ophthalmologist-in-Chief of Wills Eye Hospital in Philadelphia, PA, where she holds the William Tasman, M.D. Endowed Chair (2007-present) Professor and Chair of the Department of Ophthalmology at Sidney Kimmel Medical College at Thomas Jefferson University and Thomas Jefferson University Hospitals (present) Member of the Johns Hopkins faculty, where she held the Katharine Graham Chair in Ophthalmology (until 2007) Trained at the Wilmer Eye Institute at Johns Hopkins where she served as the first female Chief Resident.
What is the salary of Julia Haller?
As the Independent Director of Bristol-Myers Squibb Co, the total compensation of Julia Haller at Bristol-Myers Squibb Co is $78,413. There are 19 executives at Bristol-Myers Squibb Co getting paid more, with Giovanni Caforio having the highest compensation of $18,767,300.
How old is Julia Haller?
Julia Haller is 65, he's been the Independent Director of Bristol-Myers Squibb Co since 2019. There are 2 older and 33 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.
What's Julia Haller's mailing address?
Julia's mailing address filed with the SEC is C/O OUTLOOK THERAPEUTICS, INC., 485 ROUTE 1 SOUTH, BLDG F, SUITE 320, ISELIN, NJ, 08830.
Insiders trading at Bristol-Myers Squibb Co
Over the last 17 years, insiders at Bristol-Myers Squibb Co have traded over $318,151,721 worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth $6,601,565 . The most active insiders traders include Lamberto Andreotti, James M Cornelius, eGiovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of $1,682,720. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth $51,554.
What does Bristol-Myers Squibb Co do?
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
What does Bristol-Myers Squibb Co's logo look like?
Complete history of Julia Haller stock trades at Bristol-Myers Squibb Co, Eyenovia Inc, eOutlook Therapeutics Inc
Bristol-Myers Squibb Co executives and stock owners
Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include:
-
Giovanni Caforio,
Chairman of the Board, Chief Executive Officer -
Sandra Leung,
Executive Vice President, General Counsel -
Dr. Giovanni Caforio M.D.,
Chairman & CEO -
Christopher Boerner,
Executive Vice President and Chief Commercial Officer -
David Elkins,
Executive Vice President and Chief Financial Officer Member of the Leadership Team -
Rupert Vessey,
Executive Vice President, Research and Early Development Member of the Leadership Team -
Louis Schmukler,
Executive Vice President, President - Global Product Development and Supply -
David V. Elkins,
Exec. VP & CFO -
Rupert Vessey BCH, BM, DPHIL, M.A.,
Exec. VP and Pres of Research & Early Devel. -
Sandra Leung Esq.,
Exec. VP & Gen. Counsel -
Dr. Christopher S. Boerner,
Exec. VP & Chief Commercialization Officer -
Vicki Sato,
Lead Independent Director -
Matthew Emmens,
Independent Director -
Peter Arduini,
Independent Director -
Dinesh Paliwal,
Independent Director -
Theodore Samuels,
Independent Director -
Karen Vousden,
Independent Director -
Robert Bertolini,
Independent Director -
Gerald Storch,
Independent Director -
Phyllis Yale,
Independent Director -
Julia Haller,
Independent Director -
Michael Bonney,
Independent Director -
Derica Rice,
Independent Director -
Paula Price,
Independent Director -
Tim Power,
Vice President of Investor Relations -
Joseph Eid,
Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team -
Karen Santiago,
Senior Vice President, Corporate Controller -
Adam Dubow,
Senior Vice President, Chief Compliance Officer and Ethics Officer -
Paul von Autenried,
Chief Information Officer, Senior Vice President -
Elizabeth Mily,
Executive Vice President - Strategy & Business Development -
Kathryn Metcalfe,
Executive Vice President - Corporate Affairs Member of the Leadership Team -
Samit Hirawat,
Executive Vice President, Chief Medical Officer, Global Drug Development Member of the Leadership Team -
Nadim Ahmed,
Executive Vice President and President - Hematology -
John Elicker,
Executive Vice President of Investor Relations -
Ann Judge,
Chief Human Resource Officer, Senior Vice President Member of the Leadership Team -
Ann M. Powell Judge,
Exec. VP & Chief HR Officer -
Adam Dubow,
Sr. VP, Chief Compliance & Ethics Officer -
Timothy Power,
VP & Head of Investor Relations -
Paul von Autenried,
Exec. VP & Chief Information Officer -
Greg Meyers,
Exec. VP and Chief Digital & Technology Officer -
Jose Baselga,
Director -
Alan J Lacy,
Director -
Joseph C Caldarella,
VP & Financial Controller -
Anne Nielsen,
Chief Compliance & Ethics Off -
Laurie H M.D. Glimcher,
Director -
Michael Grobstein,
Director -
Togo D Jr West,
Director -
Emmanuel Blin,
SVP, Head of Commercialization -
Francis M Cuss,
SVP Dscvry & Exp Clinl Resrch -
Murdo Gordon,
SVP, Head of Worldwide Markets -
Thomas J. Jr. Lynch,
Director -
Karin Shanahan,
EVP, Glob. Prod. Dev. & Supply -
Lynelle Hoch,
President, Cell Therapy Org. -
Phil M Holzer,
SVP and Controller -
Ahn Amanda Poole,
EVP, Chief Human Resources -
Samuel J Moed,
SVP, Strat Plan & Analysis -
Michelle Weese,
EVP, Corporate Affairs -
Paul Biondi,
SVP, Head of Strategy & BD -
Charles A Bancroft,
EVP, Head of Integration -
Ann Powell,
EVP, Chief Human Resources -
Frances K Heller,
SVP, Business Development -
Brian Daniels,
SVP Global Development -
Elliot Sigal,
EVP, CSO & President R&D -
Beatrice J Cazala,
SVP Comm Ops & Pres GC Euro EM -
Robert T Zito,
SVP & Chief Comm Officer -
Jeremy M Levin,
SVP Strat Transactions -
R Sanders Williams,
Director -
Anthony C Hooper,
President US Pharmaceuticals -
Louis J Freeh,
Director -
Anthony A Mcbride,
SVP Human Resources -
De Notaristefani Carlo,
President, Tech Ops -
Leif Johansson,
Director -
John E Celentano,
SVP Strat & Productivity Trans -
Jean Marc Huet,
SVP & CFO -
James M Cornelius,
Chairman & CEO -
Lewis B Campbell,
Director -
Medina Manuel Hidalgo,
Director -
Benjamin Hickey,
President, RayzeBio Org. -
Gregory Scott Meyers,
EVP, Chief Digital & Tech Off. -
Sharon Greenlees,
SVP & Controller -
Deepak Bhatt,
Director -
Michael R. Mc Mullen,
Director -
Adam Lenkowsky,
EVP, Chief Commercial Officer -
Robert M Plenge,
EVP, Chief Research Officer -
Cari Gallman,
EVP, Corporate Affairs